RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
EyeGate Pharmaceuticals Stock

EyeGate Pharmaceuticals ROCE 2024

EyeGate Pharmaceuticals ROCE

0

Ticker

EYEG

ISIN

US30233M5031

WKN

A2PRBT

In 2024, EyeGate Pharmaceuticals's return on capital employed (ROCE) was 0, a 0% increase from the 0 ROCE in the previous year.

EyeGate Pharmaceuticals Aktienanalyse

What does EyeGate Pharmaceuticals do?

EyeGate Pharmaceuticals Inc. is a US pharmaceutical company specializing in the development of ophthalmology products. It was founded in 1998 and is headquartered in Waltham, Massachusetts. The company aims to meet the need for safe and effective therapies for the treatment of eye diseases. Its business model focuses on the development and commercialization of products that enable faster and more effective treatment of eye diseases. The company has two main divisions. The first division includes iontophoretic drug delivery technologies used for the treatment of eye diseases. Iontophoresis is a process in which electric currents are used to transport medications through the skin and into the eyes. EyeGate Pharmaceuticals has developed the EyeGate® II Delivery System technology, which allows for non-invasive, painless, and safe administration of medications into the eye. The EyeGate II Delivery System can be used for the treatment of inflammation, pain, and infections in the eye area. The second division is the development of drugs used for the treatment of eye diseases. EyeGate Pharmaceuticals has several clinical programs in development, including EGP-437, a steroid-free corticosteroid used for the treatment of inflammation of the anterior eye segment. EGP-437 is currently being tested in two clinical trials to demonstrate its efficacy and safety in the treatment of pain and inflammation in the eye. In addition, the company has developed the drug EGP-259 for the treatment of dry eye. EyeGate Pharmaceuticals has previously entered into several partnerships with other companies to further develop and commercialize its technology platform. In 2019, the company entered into a partnership with Valeant Pharmaceuticals International, Inc. to advance the marketing of EGP-437 in the United States. EyeGate Pharmaceuticals aims to continue growing and expanding its presence in the field of ophthalmology in the coming years. The company is working on the development of new products and technologies that enable it to respond to the changing needs and challenges in ophthalmology. Overall, EyeGate Pharmaceuticals is committed to developing and marketing innovative and effective technologies and drugs for the treatment of eye diseases. The company is well positioned to grow in a rapidly evolving market and make a significant contribution to improving the health and quality of life of millions of people worldwide. EyeGate Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling EyeGate Pharmaceuticals's Return on Capital Employed (ROCE)

EyeGate Pharmaceuticals's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing EyeGate Pharmaceuticals's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

EyeGate Pharmaceuticals's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in EyeGate Pharmaceuticals’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about EyeGate Pharmaceuticals stock

What is the ROCE (Return on Capital Employed) of EyeGate Pharmaceuticals this year?

The ROCE of EyeGate Pharmaceuticals is 0 undefined this year.

How has the ROCE (Return on Capital Employed) of EyeGate Pharmaceuticals developed compared to the previous year?

The ROCE of EyeGate Pharmaceuticals has increased by 0% decreased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of EyeGate Pharmaceuticals?

A high Return on Capital Employed (ROCE) indicates that EyeGate Pharmaceuticals has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of EyeGate Pharmaceuticals?

A low ROCE (Return on Capital Employed) can indicate that EyeGate Pharmaceuticals has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from EyeGate Pharmaceuticals impact the company?

An increase in the ROCE of EyeGate Pharmaceuticals can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of EyeGate Pharmaceuticals affect the company?

A decrease in ROCE of EyeGate Pharmaceuticals can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of EyeGate Pharmaceuticals?

Some factors that can affect EyeGate Pharmaceuticals's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of EyeGate Pharmaceuticals so important for investors?

The ROCE of EyeGate Pharmaceuticals is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can EyeGate Pharmaceuticals take to improve the ROCE?

To improve the ROCE, EyeGate Pharmaceuticals can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does EyeGate Pharmaceuticals pay?

Over the past 12 months, EyeGate Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, EyeGate Pharmaceuticals is expected to pay a dividend of 0.09 USD.

What is the dividend yield of EyeGate Pharmaceuticals?

The current dividend yield of EyeGate Pharmaceuticals is .

When does EyeGate Pharmaceuticals pay dividends?

EyeGate Pharmaceuticals pays a quarterly dividend. This is distributed in the months of July, August, September, October.

How secure is the dividend of EyeGate Pharmaceuticals?

EyeGate Pharmaceuticals paid dividends every year for the past 2 years.

What is the dividend of EyeGate Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0.09 USD are expected. This corresponds to a dividend yield of 0.25 %.

In which sector is EyeGate Pharmaceuticals located?

EyeGate Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von EyeGate Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of EyeGate Pharmaceuticals from 9/6/2024 amounting to 0.149 USD, you needed to have the stock in your portfolio before the ex-date on 9/3/2024.

When did EyeGate Pharmaceuticals pay the last dividend?

The last dividend was paid out on 9/6/2024.

What was the dividend of EyeGate Pharmaceuticals in the year 2023?

In the year 2023, EyeGate Pharmaceuticals distributed 0 USD as dividends.

In which currency does EyeGate Pharmaceuticals pay out the dividend?

The dividends of EyeGate Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von EyeGate Pharmaceuticals

Our stock analysis for EyeGate Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of EyeGate Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.